PortfoliosLab logoPortfoliosLab logo
TXG vs. CYBR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TXG vs. CYBR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in 10x Genomics, Inc. (TXG) and CyberArk Software Ltd. (CYBR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period


TXG

1D
-5.22%
1M
39.10%
YTD
101.96%
6M
94.45%
1Y
204.72%
3Y*
-15.51%
5Y*
-30.38%
10Y*

CYBR

1D
1M
YTD
6M
1Y
3Y*
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

TXG vs. CYBR - Yearly Performance Comparison


2026 (YTD)2025202420232022202120202019
TXG
10x Genomics, Inc.
101.96%13.58%-74.34%53.57%-75.54%5.20%85.70%41.20%
CYBR
CyberArk Software Ltd.
-8.34%33.89%52.09%68.95%-25.18%7.23%38.61%17.14%

Correlation

The correlation between TXG and CYBR is 0.12, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.12

Correlation (3Y)
Calculated over the trailing 3-year period

0.22

Correlation (5Y)
Calculated over the trailing 5-year period

0.37

Correlation (All Time)
Calculated using the full available price history since Sep 12, 2019

0.37

Over the past year, the correlation between TXG and CYBR has dropped to 0.12 - well below their long-term average of 0.37, suggesting their price drivers have been diverging.

Fundamentals

Market Cap

TXG:

$4.23B

CYBR:

$20.69B

EPS

TXG:

-$0.18

CYBR:

-$2.92

PS Ratio

TXG:

6.52

CYBR:

15.13

PB Ratio

TXG:

5.19

CYBR:

8.61

Total Revenue (TTM)

TXG:

$638.78M

CYBR:

$1.36B

Gross Profit (TTM)

TXG:

$444.61M

CYBR:

$1.01B

EBITDA (TTM)

TXG:

-$5.89M

CYBR:

$59.13M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TXG vs. CYBR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TXG
TXG Risk / Return Rank: 9393
Overall Rank
TXG Sharpe Ratio Rank: 9595
Sharpe Ratio Rank
TXG Sortino Ratio Rank: 9292
Sortino Ratio Rank
TXG Omega Ratio Rank: 8888
Omega Ratio Rank
TXG Calmar Ratio Rank: 9696
Calmar Ratio Rank
TXG Martin Ratio Rank: 9494
Martin Ratio Rank

CYBR

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TXG vs. CYBR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and CyberArk Software Ltd. (CYBR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TXGCYBRDifference
Sharpe ratioReturn per unit of total volatility

Sortino ratioReturn per unit of downside risk

Omega ratioGain probability vs. loss probability

1.39

Calmar ratioReturn relative to maximum drawdown

7.35

Martin ratioReturn relative to average drawdown

16.73

TXG vs. CYBR - Sharpe Ratio Comparison


Loading charts...

Drawdowns

TXG vs. CYBR - Drawdown Comparison


Loading charts...

Drawdown Indicators


TXGCYBRDifference

Max Drawdown

Largest peak-to-trough decline

-96.47%

Max Drawdown (1Y)

Largest decline over 1 year

-28.03%

Max Drawdown (3Y)

Largest decline over 3 years

-88.66%

Max Drawdown (5Y)

Largest decline over 5 years

-96.45%

Current Drawdown

Current decline from peak

-83.72%

Average Drawdown

Average peak-to-trough decline

-59.78%

Ulcer Index

Depth and duration of drawdowns from previous peaks

12.29%

Volatility

TXG vs. CYBR - Volatility Comparison


Loading charts...

Volatility by Period


TXGCYBRDifference

Volatility (1M)

Calculated over the trailing 1-month period

23.47%

Volatility (6M)

Calculated over the trailing 6-month period

48.22%

Volatility (1Y)

Calculated over the trailing 1-year period

69.06%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

68.74%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

66.90%

Dividends

TXG vs. CYBR - Dividend Comparison

Neither TXG nor CYBR has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

TXG vs. CYBR - Financials Comparison

This section allows you to compare key financial metrics between 10x Genomics, Inc. and CyberArk Software Ltd.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


100.00M150.00M200.00M250.00M300.00M350.00M20222023202420252026
150.84M
372.65M
(TXG) Total Revenue
(CYBR) Total Revenue
Values in USD except per share items

TXG vs. CYBR - Profitability Comparison

The chart below illustrates the profitability comparison between 10x Genomics, Inc. and CyberArk Software Ltd. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%70.0%80.0%90.0%100.0%20222023202420252026
70.4%
71.7%
Portfolio components
TXG - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported a gross profit of 106.18M and revenue of 150.84M. Therefore, the gross margin over that period was 70.4%.

CYBR - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported a gross profit of 267.25M and revenue of 372.65M. Therefore, the gross margin over that period was 71.7%.

TXG - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported an operating income of -17.05M and revenue of 150.84M, resulting in an operating margin of -11.3%.

CYBR - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported an operating income of 1.75M and revenue of 372.65M, resulting in an operating margin of 0.5%.

TXG - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, 10x Genomics, Inc. reported a net income of -13.47M and revenue of 150.84M, resulting in a net margin of -8.9%.

CYBR - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CyberArk Software Ltd. reported a net income of -17.11M and revenue of 372.65M, resulting in a net margin of -4.6%.


Frequently Asked Questions


TXG and CYBR have a correlation of 0.12, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Portfolio Optimizer

Find the right allocation for TXG and CYBR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer